Rare Disease Day: Emmes Endpoints Solutions submits Duchenne video assessment qualification plan to FDA
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Emmes, part of Emmes Group, today announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials
Download Go back to Newsroom
Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Emmes, part of Emmes Group, today announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials
Technology in Vaccine Trials
In the wake of the COVID-19 pandemic, the world has witnessed both the devastating impact of infectious diseases and the remarkable speed at which vaccines can be developed and deployed. This unprecedented crisis has underscored the need for rapid vaccine clinical trials, driven by a combination of factors: maximizing public benefits, ensuring cost-effective clinical development, and securing a competitive edge in the pharmaceutical industry.
Download Go back to Blog
In the wake of the COVID-19 pandemic, the world has witnessed both the devastating impact of infectious diseases and the remarkable speed at which vaccines can be developed and deployed. This unprecedented crisis has underscored the need for rapid vaccine clinical trials, driven by a combination of factors: maximizing public benefits, ensuring cost-effective clinical development, and securing a competitive edge in the pharmaceutical industry.
Emmes adds new role as it looks to expand government footprint
Emmes adds new role as it looks to expand government footprint
Bryan Patterson to lead as Senior Vice President of Government Business Development & Capture
Go back to Newsroom
Bryan Patterson to lead as Senior Vice President of Government Business Development & Capture
Emmes Group® names Germaine Gross Chief Commercial Officer of Emmes® Biopharma
Emmes Group® names Germaine Gross Chief Commercial Officer of Emmes® Biopharma
Strategic hire underscores Emmes Group’s growth and commitment to biopharma market
Emmes Group®, a leading specialty tech and AI-enabled global contract research organization (CRO), today announced the appointment of Germaine Gross to the role of Chief Commercial Officer, Emmes® Biopharma. This strategic hire underscores the company’s commitment to expanding its biopharma footprint, fostering innovation, and redefining excellence in the CRO industry.
Download Go back to Newsroom
Strategic hire underscores Emmes Group’s growth and commitment to biopharma market
Emmes Group®, a leading specialty tech and AI-enabled global contract research organization (CRO), today announced the appointment of Germaine Gross to the role of Chief Commercial Officer, Emmes® Biopharma. This strategic hire underscores the company’s commitment to expanding its biopharma footprint, fostering innovation, and redefining excellence in the CRO industry.